COVID-19 Antibody Registry
Play a proactive role in discovering the longevity of antibodies for COVID-19

A public, self-enrollment registry to track a large population of COVID-19 immunity responses in vaccinated participants, participants with a previous infection, and participants with previous infection who have been vaccinated

Since March 2020, the world has been navigating its way through the COVID-19 pandemic. Millions have died from COVID-19, while at the same time, many more millions have been infected with the virus and recovered. A variety of vaccines are now available to combat the virus. Both vaccines and COVID-19 recoveries create antibodies that fight off reinfection of the virus. But many questions remain that the COVID-19 Antibody Registry (CAR) hopes to provide answers for:

By learning how antibody levels increase or decrease over time, our goal is to better understand just how immunity works.

The CAR study evaluates antibody concentrations in participants who have either tested positive for COVID-19, received one of the available vaccines, or both. CAR is available to any person in the world with some sort of COVID-19 immunity who is willing to take an antibody test. Voluntary participation in this registry will require your consent to share your data without divulging your identity.

CAR data is securely stored in TrialKit’s cloud database. TrialKit is a data collection and study management solution that is compliant with 21 CFR Part 11 guidelines, GDPR, HIPAA, EMEA Annex 11, ICH Q9, ISO 9001:2015, ISO/IEC 27001:2013, SOC Type 2, Privacy Shield EU-US, and HiTrust. As enough data is aggregated, study results by time period will be published. The registry could lead to more detailed studies that collect more specific data, as well as individual tests to determine more long-term immunity. 

Participating in the CAR study is simple and straightforward:

Download TrialKit from the App Store and Google Play from any iOS or Android device
Enroll in the study as a blinded participant by providing your email address and entering the code C19AB
Provide your informed consent
Complete Baseline and Screening forms and provide redacted proof of vaccination, previous infection, or both
Take a SARS-CoV-2 Semi-Quant Total Ab venipuncture test - readily available at most Labcorp locations
Complete the Quant Ab Test Result form in TrialKit
Re-take your Semi-Quant Ab test every three months - or as needed - and submit them to CAR to follow changes in antibody levels over time

Access the CAR Instruction Guide to help you enroll today.

Questions about joining the CAR study? Get in touch with us:

Learn more about Crucial Data Solutions and TrialKit

Crucial Data Solutions, Inc. is dedicated to developing innovative technologies that reduce the cost of research when in the hands of those performing the research. We equip research professionals with advanced tools that make it easier and more affordable to advance treatments and improve the quality of life for all those involved. We approach clinical research as a partnership with research professionals, caregivers, and patients worldwide.

TrialKit, our cloud-based platform available via a web interface and downloadable native mobile app, enables end-to-end clinical trial management for pharmaceutical, biotechnology, and medical device companies of all sizes. Over 10,000 global users have leveraged the flexibility of TrialKit to deploy over 7,000 studies across all phases of drug and device development.


Close Menu

Request a Demo

Are you interested in seeing TrialKit in action? Please complete the form below, and one of our product experts will contact you to schedule a demonstration.